- IsiNgisi
- IsiFulentshi
- IsiJalimane
- Isiphepheli
- ISpanishi
- Isikhali sase-Russian
- IsiJapan
- Isikhulukazi
- I-ARABIC
- Irish
- Umphetho
- IsiTurkey
- I-Italian
- Jishibe
- IsiRomania
- I-Indonesia
- IsiCzech
- IsiBhulu
- IsiSwidi
- Khazimulisa
- IB0Que
- Catalan
- I-Esperanto
- IsiHindi
- Ilaya
- I-Albanian
- Amharic
- Umshini wase-Armenia
- Azerbaijani
- IBelarusian
- IsiBengali
- IsiBosnia
- IsiBulgaria
- Cebuano
- Chichewa
- I-corsican
- IsiCroatia
- IsiDashi
- I-Estonia
- IPhilippines
- Isithabisese
- I-frician
- Jikali
- IsiGeorgian
- IsiGujarati
- IsiHaiti
- Hausa
- I-handaiian
- IsiHeberu
- Hmong
- IsiHungary
- I-Icelandic
- Ingboza
- Javanese
- Infoura
- Kazakh
- Khmer
- UKursish
- Uhlobo lukamyz
- IsiLatini
- IsiLatvia
- I-Lithuanian
- I-Lithuanian
- IsiMacedonia
- Isilimazana elikhulu laseMalagasy
- Inyobho phakathi
- IsiMalayalam
- I-Malta
- Maori
- Marathi
- IsiMongolia
- Burmese
- Nepali
- IsiNorway
- I-Pashto
- UmPheresiya
- IsiPunjabi
- IsiSerbia
- IsiSuthu
- ISinhala
- Uhlobo lwenkanulo
- IsiSlovenia
- ISomalia
- Isihlalo samadolo
- Scots gaelic
- Shena
- USindhi
- ISundesese
- IsiSwahili
- Tajik
- Tamil
- I-telugu
- Isiswelasi
- Isi-Ukraine
- Urdu
- Uzbek
- IsiVietnam
- I-Welsh
- IsiXhosa
- I-Yiddish
- Yoruba
- IsiZulu
- Kinyarwanda
- Impinda
- Oriya
- ITurkmen
- Uyghur
I-INSIGVIght Car - T
Umlando wentuthuko wemoto - T Cell Therapy
Ukuthuthukiswa kwemoto - I-T Cell Therapy ingalandelelwa emuva ngo-1989, lapho i-Cross G kanye nolunye ososayensi abathathu bahlongoza kuqala umqondo we- "Car". Kwathi ngo-2008, i-Fred Hutchison Cancer Institute kuqala amaseli e-T Car T yokuphatha i-B - Cell Lymphoma, ekhombisa ukuphepha kwale ndlela yokwelapha. Ngo-2010, icala lokuqala eliphumelelayo le-CD19 - Ukuqondisa imoto - I-T Therapy ye-B - Iseli - Okuhlobene Nokungekho - I-Hodgkin Lymphoma kubikwa e-United States. Kwathi ngo-2011, uProfessor Carl uSifundo sika-University of Pennsylvania sathuthuka kakhulu, futhi i-Emily ephumelele yokwelashwa, i-Car Car Tr T Therapy yokwelapha entsha yokuqhuma. Ngo-2017, i-US Food and Drug Administration (FDA) ivume ukugunyazwa kokukhangisa kwe-Car T Cell Product Kymriah, okuphawula ukufika kwenkathi yezentengiselwano yamaseli emoto. Ngawo lowo nyaka, yebo-ke, imoto yesibili - Umkhiqizo Wezokwelapha Amaseli, ubuye wagunyazwa ukugunyazwa kwezentengiso. Ngo-2020, i-FDA yavuma imoto yesithathu t - I-Cell Therapy Product TECARTUS. Ngo-2021, i-FDA yavumile imoto emibili - T t I-Immunotherapy Product, Breinanzi kanye ne-ABECMA, yokwelashwa kwe-refractory noma ukuphinda i-brow B enkulu - ngokulandelana i-mEloma, ngokulandelana. Ngawo lowo nyaka, i-CDE yaseChina iphinde yavuma ukugunyazwa kokukhangisa kwemikhiqizo emibili ye-Tar T Therapy kusuka ku-Axi - Cel kanye ne-Rearma - I-CEL, yokwelashwa kwe-Breath Broad ephindaphindayo.
Ngo-2022, i-FDA yavumile ukugunyazwa kwe-Carvykti, imoto - I-T Cell Cell Therapy Product Auturation Antigen (BCMA) yokwelashwa kwe-MULELOMA engahleliwe.
Ngalesi sikhathi, ukwelashwa kweselula yeCar T kungene enkathini yomdlavuza umdlavuza futhi wavula isethulo esihle emhlabeni.
Yini imoto - t therapy cell
I-Car T Therapy Therapy, eyaziwa nangokuthi i-Chimeric Antigen Receptor T Celly ImmunoSatherapy (Imoto - T), is a emgqeni we-immunoware Lokhu kuyabavumela ukuthi babone ngokuqondile amaseli, bese befaka lawo maseli abuyele esigulini ukwelapha lesi sifo.
